ClinicalTrials.gg
RecruitingNCT07124650STONESUpdated Apr 13, 2026

Sore Throat After Open Neck Elective Surgery

A Phase 4 interventional study of Hydrocortisone Acetate 1% Ointment and Lidocaine hydrochloride 0,05% with chlorhexidine in Postoperative Sore Throat, Cough, Hoarseness and Thyroid and Parathyroid Surgery, sponsored by Saint Petersburg State University, Russia. Recruiting at 1 site in Russia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Saint Petersburg State University, Russia · Phase 4, Interventional, and Prevention

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Phase
Phase 4
Study type
Interventional
Enrollment
764
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized clinical trial aims to evaluate the effectiveness of two medications-hydrocortisone ointment and lidocaine solution-applied to the endotracheal tube in reducing postoperative throat pain, hoarseness, and cough following thyroid or parathyroid surgery with neuromonitoring.

A total of 764 adult patients undergoing elective neck surgery at Saint-Petersburg State University Hospital will be enrolled and randomly assigned to receive either a hydrocortisone-coated or lidocaine-coated endotracheal tube.

Outcomes will be assessed upon awakening from anesthesia, at 24 hours, and again at 3 days postoperatively.

The findings may contribute to improving postoperative comfort and recovery for patients undergoing similar surgical procedures.

02

Conditions studied

  • Postoperative Sore Throat, Cough, Hoarseness
  • Thyroid and Parathyroid Surgery

Keywords

  • Hydrocortisone
  • Lidocaine
  • Endotracheal tube
  • Neuromonitoring
  • Randomized controlled trial
03

In context

Cough

427 studies on the registry are indexed under Cough; 67 are open to participants now.

This study's planned enrollment of 764 is above the median of 80 across 319 interventional studies indexed under Cough.

Browse Cough studies →

Lead sponsor

Saint Petersburg State University, Russia is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective open surgery on the thyroid/parathyroid glands with intraoperative neuromonitoring.
  • Age ≥18 years.
  • Willing and able to provide voluntary for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (for women of ).
  • Known allergy to hydrocortisone or lidocaine.
  • Refusal to participate in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
764 participants (estimated)

Study arms

  • Experimental
    Hydrocortisone group

    Participants receive endotracheal tubes coated with 1% hydrocortisone ointment to reduce postoperative sore throat and hoarseness.

    Drug: Hydrocortisone Acetate 1% Ointment

  • Experimental
    Lidocaine group

    Participants receive endotracheal tubes coated with 0.05% lidocaine and chlorhexidine solution (Cathelgel).

    Drug: Lidocaine hydrochloride 0,05% with chlorhexidine

Interventions

  • Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.

  • DrugLidocaine hydrochloride 0,05% with chlorhexidine

    Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.

    Also known as: Cathejell

06

What researchers measure

Primary outcomes

  1. Frequency of severe throat pain at 24 hours post-operation

    Proportion of patients scoring ≥3 points on the STONES throat pain subscale (0 = no pain, 1 = mild, 2 = moderate, 3 = severe pain) assessed 24 hours after thyroid/parathyroid surgery. Evaluated through patient-reported questionnaire administered by a blinded investigator.

    Time frame: 24 hours post-operation

  2. Frequency of clinically significant EMG signal reduction

    Proportion of patients showing ≥50% decrease in amplitude of electromyographic (EMG) signals from recurrent laryngeal nerve during intraoperative neuromonitoring compared to baseline measurements (V1/ R1 timepoints), using the C2 neuromonitor system.

    Time frame: Perioperative/periprocedural

Secondary outcomes

  1. Frequency of intraoperative laryngeal reflexes (coughing)

    Number of coughing episodes recorded by anesthesiologist during surgical procedure, graded as: 0 = no cough, 1 = single mild cough, 2 = persistent cough requiring intervention.

    Time frame: Perioperative/periprocedural

  2. Episodes of complete EMG signal loss during surgery

    Number of events with total loss of electromyographic response (OmV amplitude) during stimulation of recurrent laryngeal nerve, confirmed by repeated measurements at standard timepoints (V1/R1 to V2/R2).

    Time frame: Perioperative/periprocedural

  3. Vocal cord mobility impairment (laryngoscopy)

    Presence of unilateral/bilateral vocal cord paralysis or paresis detected through postoperative fiberoptic laryngoscopic examination, graded as: 0 = normal mobility, 1 = reduced mobility, 2 = complete paralysis."

    Time frame: 72 hours after surgery

  4. Neck Disability Index (NDI) score

    Patient-reported functional limitation score (0-50 scale) assessing neck pain impact on daily activities, with higher scores indicating greater disability. Collected through standardized questionnaire.

    Time frame: 3 days after surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Row data may be shared by the reasonable request

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07124650
Lead sponsor
Saint Petersburg State University, Russia
Collaborators
Smooth Drug Development
Responsible party
Efremov Sergey (Deputy director for science, Saint-Petersburg state university hospital, Saint Petersburg State University, Russia) — Principal investigator
First posted
Aug 15, 2025
Start date
Sep 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
May 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Sergey M. Efremov, D. Med. Sc.
Contact
efremovsergm@gmail.com
+79137946090
Alexey Y. Kulikov, Ph. D. (Med.)
Contact
alexeykulikov1987@yandex.ru
+79217896909
Sergey M. Efremov, MD, PhD
principal investigator · Saint Petersburg State University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydrocortisone acetate

Start the discussion